where was glp 1 discovered Historical timeline of GLP-1 biology, receptor agonist discovery, and Frontiers | Beyond GLP-1: underexplored

It contains ingredients that may support metabolic function and healthy appetite patterns.*

In addition to outcomes data, payers will be guided by cost-effectiveness considerations, e.g., as assessed by European HTA bodies or ICER, with implications for drug prices to meet acceptable cost-effectiveness thresholds

Leading diabetes players Novo Nordisk and Lilly are set to dominate the race for the obesity opportunity

Gentle on the stomach

Each has demonstrated the potential to emerge as either a Best-in-Class or First-in-Class treatment in the obesity field.The ADA 2025 presentations will cover: Phase 1 Trial Results for HM15275, Robust anti-obesity effect and mechanistic insights of HM15275 in animal models of obesity, Mechanistic insights into HM15275s improved quality of weight loss compared to tirzepatide (Zepbound), Weight loss and differentiated body composition improvement effects of HM17321, Glycemic control improvement observed with HM17321, and Synergistic effects on body composition improvement when combining HM15275 and HM17321A large delegation from Hanmis R&D Center will attend ADA 2025 to present poster sessions showcasing the companys novel therapeutic approaches in obesity treatment and to explore potential collaborations with leading global pharmaceutical companies. HM15275: Next-Generation Triple Agonist Targeting Quantity and Quality of Weight LossHM15275 is engineered to optimize the activity balance of GLP-1, GIP, and glucagon (GCG) receptors, delivering targeted obesity treatment while also addressing comorbid metabolic conditions such as diabetes, cardiovascular, and renal disease